Trial intelligence / Profile preview

AC-MIT regimen in newly diagnosed angioimmunoblastic T cell lymphoma

ChiCTR2300079201Phase 4Recruiting

Sponsor
First Affiliated Hospital, Zhejiang University School of Medicine
Start
Dec 2023
Modality
DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of azacitidine, tucidinostat and mitoxantrone in angioimmunoblastic T-cell lymphoma (AITL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete response rate. Started Dec 2023; status: recruiting.

02

Drugs

azacitidinetucidinostatmitoxantrone
03

Conditions

angioimmunoblastic T-cell lymphoma (AITL)

Beyond the preview

Go deeper on ChiCTR2300079201.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2300079201.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call